Law360, New York (April 27, 2006, 12:00 AM ET) -- After months of negotiations, U.K. drug maker Shire Pharmaceuticals said this week it remains optimistic about talks with Barr Laboratories to try to settle out of court a patent challenge to Shire’s blockbuster hyperactivity drug Adderall XR.
The two companies are involved in litigation concerning Barr's efforts to market a copycat version of Shire's Adderall XR prior to the expiration of the Shire patents, which are not set to expire until 2018.
The two companies have remained tight-lipped concerning the negotiations, which have been ongoing since...
Shire “Encouraged” By Settlement Talks Over Adderall
To view the full article, take a free trial now.
